ReviewDrugs2008
Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview.
Review in Drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 50 citations in OpenAlex.
- Memory T Cells in Transplantation: Old Challenges Define New Directions.Transplantation · 2020Review
- B cell-derived IL-1β and IL-6 drive T cell reconstitution following lymphoablation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Article
- PTPN22 Acts in a Cell Intrinsic Manner to Restrict the Proliferation and Differentiation of T Cells Following Antibody Lymphodepletion.Frontiers in immunology · 2020Article
- Bioprinting an Artificial Pancreas for Type 1 Diabetes.Current diabetes reports · 2019Review
- Role of Memory T Cells in Allograft Rejection and Tolerance.Frontiers in immunology · 2017Review
- Update on Dendritic Cell-Induced Immunological and Clinical Tolerance.Frontiers in immunology · 2017Review
- CD4 T Cell Help via B Cells Is Required for Lymphopenia-Induced CD8 T Cell Proliferation.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Activation of the peroxisome proliferator-activated receptor γ counteracts sepsis-induced T cell cytotoxicity toward alloantigenic target cells.Journal of molecular medicine (Berlin, Germany) · 2015Article
- A retrospective study of cytomegalovirus pneumonia in renal transplant patients.Experimental and therapeutic medicine · 2014Article
- Pretransplant antithymocyte globulin has increased efficacy in controlling donor-reactive memory T cells in mice.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2013Article
- Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model.PloS one · 2013Article
- Preserving the B-cell compartment favors operational tolerance in human renal transplantation.Molecular medicine (Cambridge, Mass.) · 2012Article
- Transplant tolerance: bench to bedside--26th annual Samuel Jason Mixter Lecture.Archives of surgery (Chicago, Ill. : 1960) · 2011Article
- Clinical operational tolerance after renal transplantation: current status and future challenges.Annals of surgery · 2010Review
- Stem cells--meet immunity.Journal of molecular medicine (Berlin, Germany) · 2009Review
- Face allotransplantation and burns: a review.Journal of burn care & research : official publication of the American Burn AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The significant development of immunosuppressive drug therapies within the past 20 years has had a major impact on the outcome of clinical solid organ transplantation, mainly by decreasing the incidence of acute rejection episodes and improving short-term patient and graft survival. However, long-term results remain relatively disappointing because of chronic allograft dysfunction and patient morbidity or mortality, which is often related to the adverse effects of immunosuppressive treatment. Thus, the induction of specific immunological tolerance of the recipient towards the allograft remains an important objective in transplantation. In this article, we first briefly describe the mechanisms of allograft rejection and immune tolerance. We then review in detail current tolerogenic strategies that could promote central or peripheral tolerance, highlighting the promises as well as the remaining challenges in clinical transplantation. The induction of haematopoietic mixed chimerism could be an approach to induce robust central tolerance, and we describe recent encouraging reports of end-stage kidney disease patients, without concomitant malignancy, who have undergone combined bone marrow and kidney transplantation. We discuss current studies suggesting that, while promoting peripheral transplantation tolerance in preclinical models, induction protocols based on lymphocyte depletion (polyclonal antithymocyte globulins, alemtuzumab) or co-stimulatory blockade (belatacept) should, at the current stage, be considered more as drug-minimization rather than tolerance-inducing strategies. Thus, a better understanding of the mechanisms that promote peripheral tolerance has led to newer approaches and the investigation of individualized donor-specific cellular therapies based on manipulated recipient regulatory T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.